knowledge -WSS

knowledge

author：comprehensive 2025-10-01 00:46:31 - browse：6123

Adam's take main illustration — Molly Ferguson/STAT

It took Anavex Life Sciences seven months to finally acknowledge the failure of a late-stage clinical trial in Rett syndrome.

The negative study outcome was never in doubt, so the only surprise from Tuesday’s announcement was the company’s lame attempt at damage control. Anavex is a serial dissembler of clinical trial results, so I was expecting better spin. Instead, management barely tried, which tells you the real results from the Rett study must be truly awful.

Anavex shares fell 31% to $6 in early trading. The company’s only drug in clinical development, called blarcamesine, is a zero. Rett is the latest failure, following earlier study failures in Alzheimer’s disease and Parkinson’s disease. Yet even with Tuesday’s drop in share price, Anavex still carries a fully diluted market value of nearly $650 million.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Long Covid needs a new name — and a new frame

Wikipedia

WSS

Long Covid needs a new name — and a new frame

Hospitals consider fixing cancer drug shortages on their own

FDA proposes changes to key medical devices approval pathway

FDA approves updated Covid vaccines

White House announces new plan to address the growing threat of xylazine in overdose crisis

FDA approves updated Covid vaccines

hotspot

knowledge

hotspot

Bright Health sells Medicare Advantage business to Molina

Medicare wants to send $9 billion to 340B hospitals

Trump demands the U.S. pay no more for drugs than other countries … again

The aspartame in Diet Coke probably isn’t giving you cancer

Affirmative action in medical school literally saved lives

Swim instructor mom warns parents not to buy blue swimsuits for kids

Novavax promises a turnaround & Lilly roils the obesity market

Presidential fundraising highlights so far: Trump brings in more than DeSantis

Jerome Adams on the need for new antivirals for Covid

Biden targets hefty hospital 'facility fees' that often surprise patients

hotspot

Will the IRA bring competition to the biologics market?

Giraffe named Twiga, who was among the oldest cared for by humans, died at age 31 at East Texas zoo

White House announces new plan to address the growing threat of xylazine in overdose crisis

Biden declares emergency in flood

FDA approves updated Covid vaccines

Eisai exec who led development of Alzheimer’s drug to retire

hotspot

Wikipedia

hotspot

explore